Anti-HMG-CoA reductase, antioxidant, anti-urease potentials, and anti-leukemia properties of 4-Butylresorcinol as a potential treatment for hypercholesterolemia

Leukemia is a type of dangerous cancer in humans. Many efforts have been done to find effective drugs to treat leukemia. One of the suitable options is the antioxidant molecules. Thus, the discovery of novel metabolites against cancer cells is of interest in current biomedicine. HMG-CoA Reductase activity was determined according to the method described by Takahashi S. et al. The MTT protocol was applied to determine the anti-leukemia potentials of 4-Butylresorcinol. Because of the 4-Butylresorcinol study, IC50 of HMG-CoA reductase enzyme: 182.04 micromolar was obtained, for urease IC50 was 91.44 micromolar. Molecular docking calculations were made to learn the theoretical activities of the 4-Butylresorcinol against the 3-hydroxy-3-methylglutaryl Coenzyme A (HMG-CoA) reductase reductase (PDB ID: 4I6A) and urease enzyme (PDB ID: 4H9M). Afterward, ADME/T calculations were made so that the molecule could be used as a drug. Additionally, the anticancer effects of molecule samples against the leukemia cells (KASUMI-1, HL-60, THP-1‎, K-562‎, RS4;11‎, and MOLT-4‎) were investigated. The aim of this study is to find a candidate compound for drug design that we recorded 4-Butylresorcinol as a good inhibitor and as an anticancer potential.